Valeo Pharma has acquired the rights to commercialize Novartis’ Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate) DPIs in Canada, the company said. Terms of the deal were not announced.
Valeo CEO Steve Saviuk said, “We are extremely pleased to be partnering with Novartis to launch these two asthma drugs in the coming weeks. Commercializing Enerzair Breezhaler and Atectura Breezhaler will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually. This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”
Valeo President and Chief Operating Officer Frederic Fasano added, “Enerzair Breezhaler and Atectura Breezhaler are both benefitting from an extensive Phase 3 clinical trial program including more than 7,500 asthma patients. The efficacy of both treatments on symptoms, lung function, and rate of exacerbations have been demonstrated and this will provide Canadian patients with a significant improvement over current standards of care. This significant addition to our expanding product portfolio is key to achieving our growth objectives. It will provide the basis for the upscaling of our organization and set the stage for future international expansion.”
Novartis Pharmaceuticals Canada General Manager Andrea Marazzi commented, “This agreement with Valeo Pharma fits with our overall strategy to provide innovative medicines that have the potential to improve health outcomes. Valeo’s commitment and focus to bring Enerzair Breezhaler and Atectura Breezhaler to Canadians, combined with our strong respiratory experience, brings a solution that will help make asthma control a more attainable goal for some Canadians.”
Enerzair Breezhaler (QVM149) and Atectura Breezhaler (QMF149) are also approved in Europe and in Japan.
Read the Valeo Pharma press release.
